Compare Amphastar Pharmaceuticals Inc (AMPH) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Charles Schwab Corporation Common Stock trades at $107.65 (market cap $186.75B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 216.2× Amphastar Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SCHW | |
|---|---|---|
Market Cap | $863.95M | $186.75B |
Sector | Health | Financials |
52-Week High | $30.81 | $108.02 |
52-Week Low | $16.87 | $85.35 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Charles Schwab (SCHW) trades at $107.60, down 0.06% on the day, near its all-time high of $109.05. The stock shows strong bullish momentum with earnings beats in recent quarters and a consensus analyst price target of $122.33. Revenue grew to $23.92 billion in 2025, with net income margin improving to 38.79%. Technical indicators signal bullish trends, though RSI levels suggest overbought conditions.
Outlook remains positive with robust earnings growth and institutional support, but risks include litigation exposure and competitive pressures. The stock offers upside potential aligned with analyst targets, contingent on sustained operational performance and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
